US FDA grants orphan drug status to IN8bio’s INB-400 and INB-410
Pharmaceutical Technology
APRIL 26, 2023
The US Food and Drug Administration (FDA) has granted orphan drug designation to IN8bio’s INB-400 and INB-410 to treat a range of malignant gliomas, including newly diagnosed glioblastoma multiforme (GBM). This marks the first-ever designation for genetically modified gamma-delta T cell therapies.
Let's personalize your content